Roberto Ceravolo

List of Publications by Year
in descending order

245	9,209	47004 47	58576 82
papers	citations	h-index	g-index

250	250	250	9857
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adult-onset mitochondrial movement disorders: a national picture from the Italian Network. Journal of Neurology, 2022, 269, 1413-1421.	3.6	10
2	Bipolar Spectrum disorders in Parkinsonâ€™s disease: a systematic evaluation. CNS Spectrums, 2022, 27, 355-361.	1.2	6
3	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. Movement Disorders Clinical Practice, 2022, 9, 6-19.	1.5	21
4	Early Compensatory Mechanisms in <scp>LRRK2</scp> Mutation Carriers. Movement Disorders, 2022, 37, 662-663.	3.9	0
5	Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinsonâ€™s disease?. Neurological Sciences, 2022, 43, 3641-3647.	1.9	3
6	Negative <scp>DATâ€SPECT</scp> in Old Onset Parkinson's Disease: An Additional Pitfall?. Movement Disorders Clinical Practice, 2022, 9, 530-534.	1.5	1
7	Fluid Biomarkers in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics, 2022, 12, 796.	2.6	4
8	Dysphagia in Parkinson's disease: Pharyngeal manometry and fiberoptic endoscopic evaluation. Auris Nasus Larynx, 2022, 49, 986-994.	1.2	4
9	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. Movement Disorders, 2022, 37, 1272-1281.	3.9	17
10	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimerâ€™s disease. Expert Review of Molecular Diagnostics, 2022, 22, 411-425.	3.1	4
11	Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. International Journal of Molecular Sciences, 2022, 23, 5393.	4.1	9
12	Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. European Journal of Neurology, 2022, 29, 2944-2955.	3.3	4
13	Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. NeuroImage, 2022, 260, 119454.	4.2	8
14	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. Movement Disorders, 2021, 36, 681-689.	3.9	22
15	Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. Movement Disorders, 2021, 36, 124-132.	3.9	22
16	Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. Journal of Neurology, 2021, 268, 1561-1569.	3.6	39
17	Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?. Neurological Sciences, 2021, 42, 723-726.	1.9	5
18	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of â€œorganicâ€•neurology. European Journal of Neurology, 2021, 28, 1752-1758.	3.3	45

#	Article	IF	Citations
19	Prevalence and impact of COVID-19 in Parkinsonâ€™s disease: evidence from a multi-center survey in Tuscany region. Journal of Neurology, 2021, 268, 1179-1187.	3.6	70
20	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. Neurological Sciences, 2021, 42, 1483-1490.	1.9	3
21	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 448-454.	3.6	16
22	Progress regarding the context-of-use of tau as biomarker of Alzheimerâ€™s disease and other neurodegenerative diseases. Expert Review of Proteomics, 2021, 18, 27-48.	3.0	8
23	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. Frontiers in Psychology, 2021, 12, 546476.	2.1	2
24	Î±-Synuclein Heteromers in Red Blood Cells of Alzheimerâ€™s Disease and Lewy Body Dementia Patients. Journal of Alzheimer's Disease, 2021, 80, 885-893.	2.6	9
25	Understanding the Multiple Role of Mitochondria in Parkinsonâ€™s Disease and Related Disorders: Lesson From Genetics and Proteinâ€“Interaction Network. Frontiers in Cell and Developmental Biology, 2021, 9, 636506.	3.7	44
26	Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. Neurology, 2021, 96, e2861-e2873.	1.1	18
27	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 2302.	2.4	8
28	Functional motor phenotypes: to lump or to split?. Journal of Neurology, 2021, 268, 4737-4743.	3.6	25
29	Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinsonâ€™s Disease Patients. Genes, 2021, 12, 720.	2.4	14
30	P2X7 receptor/NLRP3 inflammasome complex and Î±â€synuclein in peripheral blood mononuclear cells: a prospective study in neoâ€diagnosed, treatmentâ€naÃ¯ve Parkinsonâ€™s disease. European Journal of Neurology, 2021, 28, 2648-2656.	3.3	12
31	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. Parkinsonism and Related Disorders, 2021, 87, 70-74.	2.2	8
32	Statins in Parkinsonâ€™s Disease: Influence on Motor Progression. Journal of Parkinson's Disease, 2021, 11, 1651-1662.	2.8	8
33	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967.	2.8	4
34	Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C. BMC Neurology, 2021, 21, 328.	1.8	5
35	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. Movement Disorders, 2021, 36, 2703-2705.	3.9	1
36	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. Movement Disorders Clinical Practice, 2021, 8, 1107-1111.	1.5	5

#	Article	IF	Citations
37	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. Journal of Alzheimer's Disease, 2021, 84, 757-766.	2.6	1
38	Reply to: â€œExperience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsyâ€. Movement Disorders, 2021, 36, 2208-2209.	3.9	0
39	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	2.2	4
40	Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review. International Journal of Molecular Sciences, 2021, 22, 11234.	4.1	19
41	The Molecular Neuroimaging of Tremor. Current Neurology and Neuroscience Reports, 2021, 21, 74.	4.2	2
42	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 798191.	2.4	13
43	Midbrain MRI assessments in progressive supranuclear palsy subtypes. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 98-103.	1.9	39
44	Extended release levodopa at bedtime as a treatment for nocturiain Parkinson's disease: An open label study. Journal of the Neurological Sciences, 2020, 410, 116625.	0.6	13
45	Confabulations in Cases of Dementia: Atypical Early Sign of Alzheimerâ€™s Disease or Misleading Feature in Dementia Diagnosis?. Frontiers in Psychology, 2020, 11, 553886.	2.1	2
46	Cerebello-thalamo-cortical network is intrinsically altered in essential tremor: evidence from a resting state functional MRI study. Scientific Reports, 2020, 10, 16661.	3.3	50
47	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Review of Proteomics, 2020, 17, 543-559.	3.0	16
48	Idiopathic <scp>Nonâ€taskâ€Specific</scp> Upper Limb Dystonia, a Neglected Form of Dystonia. Movement Disorders, 2020, 35, 2038-2045.	3.9	21
49	Fluid Candidate Biomarkers for Alzheimerâ€™s Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221.	2.5	20
50	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 2020, 57, 4667-4691.	4.0	33
51	Impact of <scp>Coronavirus Disease 20</scp>19 Pandemic on Cognition in Parkinson's Disease. Movement Disorders, 2020, 35, 1717-1718.	3.9	30
52	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders Clinical Practice, 2020, 7, 920-929.	1.5	45
53	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology, 2020, 95, e2854-e2865.	1.1	25
54	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. Journal of Neural Transmission, 2020, 127, 1435-1439.	2.8	22

#	Article	IF	Citations
55	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. Frontiers in Neurology, 2020, 11, 906.	2.4	6
56	Red blood cell Î±â€synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the ADâ€LBD spectrum. Alzheimer's and Dementia, 2020, 16, e040618.	0.8	0
57	Sex differences in red blood cell Î± â€synuclein protein and its heteroaggregates with amyloidâ€Î² and tau in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042079.	0.8	0
58	Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelaninâ€3T MRI. Alzheimer's and Dementia, 2020, 16, e043332.	0.8	0
59	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimerâ€™s disease and other types of dementia. Alzheimer's and Dementia, 2020, 16, e043616.	0.8	0
60	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain, 2020, 143, 1780-1797.	7.6	66
61	Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. Journal of Neurology, 2020, 267, 2556-2566.	3.6	13
62	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. Journal of Neurology, 2020, 267, 2949-2960.	3.6	26
63	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Singleâ€Photon Emission Computed Tomography Study. Movement Disorders, 2020, 35, 1028-1036.	3.9	17
64	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between Î±-synucleinopathies. Journal of Neurology, 2020, 267, 3444-3456.	3.6	17
65	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441.	3.1	42
66	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. Movement Disorders, 2020, 35, 976-983.	3.9	38
67	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. Parkinsonism and Related Disorders, 2020, 71, 40-43.	2.2	18
68	Theory of mind in Parkinsonâ€™s disease: evidences in drug-naÃ¯ve patients and longitudinal effects of dopaminergic therapy. Neurological Sciences, 2020, 41, 2761-2766.	1.9	4
69	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. Frontiers in Neurology, 2020, 11, 207.	2.4	15
70	Tardive Syndrome Associated With Tetrabenazine in Huntington Disease. Journal of Clinical Psychopharmacology, 2020, 40, 628-630.	1.4	2
71	Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research. Neural Regeneration Research, 2020, 15, 1650.	3.0	11
72	Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease. European Journal of Neurology, 2019, 26, 74-79.	3.3	14

#	Article	IF	Citations
73	Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. Parkinsonism and Related Disorders, 2019, 66, 40-44.	2.2	9
74	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Movement Disorders Clinical Practice, 2019, 6, 576-585.	1.5	36
75	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	1.9	5
76	Molecular Imaging of the Dopamine Transporter. Cells, 2019, 8, 872.	4.1	62
77	Quantitative susceptibility mapping in atypical Parkinsonisms. NeuroImage: Clinical, 2019, 24, 101999.	2.7	49
78	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	5
79	Clinical Correlates of Cerebral Amyloid Deposition in Parkinsonâ€™s Disease Dementia: Evidence from a PET Study. Journal of Alzheimer's Disease, 2019, 70, 597-609.	2.6	13
80	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in Î±-synucleinopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1257-1263.	1.9	73
81	OC.05.3 HISTOMORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: A PILOT STUDY. Digestive and Liver Disease, 2019, 51, e89.	0.9	0
82	Freezing of gait and dementia in parkinsonism: A retrospective caseâ€“control study. Brain and Behavior, 2019, 9, e01247.	2.2	8
83	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. Brain and Behavior, 2019, 9, e01182.	2.2	5
84	Potential Diagnostic Value of Red Blood Cells Î±-Synuclein Heteroaggregates in Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 6451-6459.	4.0	24
85	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 301-309.	2.4	30
86	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 159-165.	2.2	20
87	Progression of tremor in early stages of Parkinsonâ€™s disease: a clinical and neuroimaging study. Brain, 2018, 141, 811-821.	7.6	107
88	Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders. Current Neurology and Neuroscience Reports, 2018, 18, 31.	4.2	10
89	Effect of type D personality on smoking status and their combined impact on outcome after acute myocardial infarction. Clinical Cardiology, 2018, 41, 321-325.	1.8	21
90	Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report. Neurological Sciences, 2018, 39, 1497-1499.	1.9	0

#	Article	IF	Citations
91	Aerobic rehabilitation program for improving muscle function in Parkinsonâ€™s disease. Restorative Neurology and Neuroscience, 2018, 36, 13-20.	0.7	5
92	Oxidative Stress Assessment in Alzheimerâ€™s Disease: A Clinic Setting Study. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 35-41.	1.9	15
93	The Precuneus â€“ A Witness for Excessive AÎ² Gathering in Alzheimerâ€™s Disease Pathology. Neurodegenerative Diseases, 2018, 18, 302-309.	1.4	13
94	Arterial stiffness and mitral regurgitation in arterial hypertension: an intriguing pathophysiological link. Vascular Pharmacology, 2018, 111, 71-76.	2.1	4
95	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2018, 19, 1643-1653.	1.8	9
96	Social Cognition and Oxytocin in Huntingtonâ€™s Disease: New Insights. Brain Sciences, 2018, 8, 161.	2.3	11
97	Î±-Synuclein Heterocomplexes with Î²-Amyloid Are Increased in Red Blood Cells of Parkinsonâ€™s Disease Patients and Correlate with Disease Severity. Frontiers in Molecular Neuroscience, 2018, 11, 53.	2.9	51
98	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods in Molecular Biology, 2018, 1750, 139-155.	0.9	12
99	Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntingtonâ€™s Disease: Relationships with Social Cognition Symptoms. Archives Italiennes De Biologie, 2018, 156, 27-39.	0.4	15
100	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	3.9	88
101	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
102	Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. Scientific Reports, 2017, 7, 39471.	3.3	108
103	The Italian Dystonia Registry: rationale, design and preliminary findings. Neurological Sciences, 2017, 38, 819-825.	1.9	35
104	Gait dynamics in Pisa syndrome and Camptocormia: The role of stride length and hip kinematics. Gait and Posture, 2017, 57, 130-135.	1.4	22
105	Efficacy of a combined therapeutic approach in the management of Pisa Syndrome. NeuroRehabilitation, 2017, 41, 249-253.	1.3	6
106	Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection. Current Opinion in Neurology, 2017, 30, 416-426.	3.6	19
107	A single center study: AÎ²42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. Neurological Sciences, 2017, 38, 1791-1797.	1.9	16
108	Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2017, 43, 105-109.	2.2	23

#	Article	IF	Citations
109	Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients. Clinical Neuropharmacology, 2017, 40, 34-36.	0.7	10
110	Antipsychotic drugs in Huntingtonâ€™s disease. Expert Review of Neurotherapeutics, 2017, 17, 227-237.	2.8	27
111	Factors influencing psychological well-being in patients with Parkinsonâ€™s disease. PLoS ONE, 2017, 12, e0189682.	2.5	32
112	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. Parkinsonism and Related Disorders, 2016, 27, 81-84.	2.2	24
113	Leadless cardiac pacemaker implant in a patient with two deep brain stimulators: A peaceful cohabitation beyond prejudices. International Journal of Cardiology, 2016, 223, 136-138.	1.7	4
114	Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?. Journal of the Neurological Sciences, 2016, 366, 167-170.	0.6	12
115	A review of adverse events linked to dopamine agonists in the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Safety, 2016, 15, 181-198.	2.4	30
116	Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. Journal of Neural Transmission, 2016, 123, 509-513.	2.8	16
117	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. Movement Disorders, 2015, 30, 1148-1149.	3.9	18
118	Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntingtonâ€™s Disease. PLoS ONE, 2015, 10, e0125259.	2.5	18
119	Cataract Surgery under Topical Anesthesia in a Patient with Parkinson Disease and Deep Brain Stimulation: A Report of Feasibility. European Journal of Ophthalmology, 2015, 25, 258-259.	1.3	0
120	Doctor â€“ how quickly will my Parkinson's progress?. European Journal of Neurology, 2015, 22, 421-422.	3.3	2
121	Clinical variables associated with treatment changes in Parkinsonâ€™s disease: results from the longitudinal phase of the REASON study. Neurological Sciences, 2015, 36, 935-943.	1.9	6
122	Morphometric and functional MRI changes in essential tremor with and without resting tremor. Journal of Neurology, 2015, 262, 719-728.	3.6	39
123	Apomorphine hydrochloride for the treatment of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 723-732.	2.8	21
124	Reliability of administrative data for the identification of Parkinsonâ€™s disease cohorts. Neurological Sciences, 2015, 36, 783-786.	1.9	23
125	Mesolimbic dopaminergic dysfunction in Parkinsonâ€™s disease depression: evidence from a 123I-FP-CIT SPECT investigation. Journal of Neural Transmission, 2015, 122, 1143-1147.	2.8	23
126	A multidisciplinary consensus document on followâ€up strategies for patients treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2015, 85, E129-39.	1.7	6

#	Article	IF	Citations
127	Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease. American Journal of Neuroradiology, 2015, 36, 461-466.	2.4	80
128	Pisa syndrome in Parkinson disease. Neurology, 2015, 85, 1769-1779.	1.1	72
129	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. Neurodegenerative Diseases, 2015, 15, 271-280.	1.4	3
130	Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. Acta Neurologica Scandinavica, 2015, 131, 191-195.	2.1	26
131	Current treatment and future prospects of dopa-induced dyskinesias. Drugs of Today, 2015, 51, 315.	1.1	14
132	MR Imaging of the Substantia Nigra for the Diagnosis of Parkinson Disease. Radiology, 2014, 273, 627-628.	7.3	1
133	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. Clinical Neuropharmacology, 2014, 37, 166-172.	0.7	1
134	Symptomatic orthostatic tremor associated with Gravesâ€™ disease. Neurological Sciences, 2014, 35, 929-931.	1.9	10
135	A pilot psychometric study of aberrant salience state in patients with Parkinsonâ€™s disease and its association with dopamine replacement therapy. Neurological Sciences, 2014, 35, 1603-1605.	1.9	4
136	MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease. Radiology, 2014, 271, 831-838.	7.3	114
137	Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology, 2014, 83, 215-220.	1.1	98
138	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. Schizophrenia Research, 2014, 152, 344-349.	2.0	38
139	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism and Related Disorders, 2014, 20, 671-672.	2.2	31
140	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. Parkinsonism and Related Disorders, 2014, 20, 761-765.	2.2	30
141	Adherence to anti-Parkinson drug therapy in the â€œREASONâ€•sample of Italian patients with Parkinsonâ€™s disease: the linguistic validation of the Italian version of the â€œMorisky Medical Adherence scale-8 itemsâ€• Neurological Sciences, 2013, 34, 2015-2022.	1.9	29
142	Diagnosis, assessment and management of delusional jealousy in Parkinsonâ€™s disease with and without dementia. Neurological Sciences, 2013, 34, 1537-1541.	1.9	14
143	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. Neuroscience Letters, 2013, 556, 1-4.	2.1	34
144	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. Parkinsonism and Related Disorders, 2013, 19, 1130-1135.	2.2	16

#	Article	IF	Citations
145	Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. Movement Disorders, 2013, 28, 1391-1397.	3.9	114
146	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naÃ¯ve patients with Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 124-131.	1.3	26
147	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. Parkinsonism and Related Disorders, 2013, 19, 800-805.	2.2	13
148	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. Parkinsonism and Related Disorders, 2013, 19, 557-559.	2.2	33
149	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. Journal of Clinical Psychopharmacology, 2013, 33, 691-694.	1.4	79
150	Mild affective symptoms in de novo <scp>P</scp>arkinson's disease patients: relationship with dopaminergic dysfunction. European Journal of Neurology, 2013, 20, 480-485.	3.3	52
151	Expanding the clinical phenotype of DYT5 mutations: Is multiple system atrophy a possible one?. Neurology, 2013, 81, 301-302.	1.1	10
152	A Systematic Review of Catechol-O-Methyltransferase Inhibitors. Clinical Neuropharmacology, 2012, 35, 185-190.	0.7	43
153	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 601-606.	1.9	130
154	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinsonâ€™s Disease. Frontiers in Neurology, 2012, 3, 159.	2.4	31
155	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. Movement Disorders, 2012, 27, 1706-1706.	3.9	9
156	Dopamine agonists and delusional jealousy in Parkinson's disease: A crossâ€sectional prevalence study. Movement Disorders, 2012, 27, 1679-1682.	3.9	48
157	The progression of non-motor symptoms in Parkinsonâ€™s disease and their contribution to motor disability and quality of life. Journal of Neurology, 2012, 259, 2621-2631.	3.6	188
158	Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinsonâ€™s disease patients. Parkinsonism and Related Disorders, 2012, 18, 59-62.	2.2	51
159	The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism and Related Disorders, 2012, 18, 775-780.	2.2	58
160	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2269-2280.	1.8	25
161	Depressive symptoms in Parkinson's disease. Comprehensive Psychiatry, 2012, 53, 727-731.	3.1	9
162	[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophrenia Research, 2012, 139, 40-45.	2.0	32

#	Article	IF	Citations
163	A molecular signature in blood identifies early Parkinsonâ€™s disease. Molecular Neurodegeneration, 2012, 7, 26.	10.8	99
164	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurological Sciences, 2012, 33, 585-593.	1.9	18
165	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. Movement Disorders, 2012, 27, 330-332.	3.9	6
166	Movement disorders: role of imaging in diagnosis. Journal of Magnetic Resonance Imaging, 2012, 35, 239-256.	3.4	39
167	Movement disorders: role of imaging in diagnosis. Journal of Magnetic Resonance Imaging, 2012, 35, spcone-spcone.	3.4	0
168	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE, 2011, 6, e18301.	2.5	84
169	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E26-E26.	1.8	0
170	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. Journal of the International Neuropsychological Society, 2011, 17, 1158-1162.	1.8	12
171	Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients. European Journal of Neurology, 2011, 18, 842-849.	3.3	32
172	The association between motor subtypes and alexithymia in de novo Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 1042-1045.	3.6	30
173	Impulsivity and compulsivity in drugâ€naÃ¯ve patients with Parkinson's disease. Movement Disorders, 2011, 26, 464-468.	3.9	139
174	Alexithymia Is Associated with Depression in de novo Parkinsonâ€™s Disease. Psychotherapy and Psychosomatics, 2011, 80, 251-253.	8.8	28
175	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. Functional Neurology, 2011, 26, 127-31.	1.3	9
176	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E26-E26.	1.8	0
177	The hOGG1 Ser326Cys polymorphism and Huntington's disease. Toxicology, 2010, 278, 199-203.	4.2	27
178	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Journal of Neurology, 2010, 257, 5-14.	3.6	140
179	Spectrum of addictions in Parkinsonâ€™s disease: from dopamine dysregulation syndrome to impulse control disorders. Journal of Neurology, 2010, 257, 276-283.	3.6	38
180	Decision making in de novo Parkinson's disease. Movement Disorders, 2010, 25, 1432-1436.	3.9	56

#	Article	IF	Citations
181	Parkinson's Disease and pathological gambling: Results from a functional MRI study. Movement Disorders, 2010, 25, 2449-2453.	3.9	57
182	Differences in nigroâ€striatal impairment in clinical variants of early Parkinsonâ€™s disease: evidence from a FPâ€CIT SPECT study. European Journal of Neurology, 2010, 17, 626-630.	3.3	75
183	Deep Brain Stimulation of Pedunculopontine Tegmental Nucleus (PPTg) Promotes Cognitive and Metabolic Changes: A Target-Specific Effect or Response to a Low-Frequency Pattern of Stimulation?. Clinical EEG and Neuroscience, 2010, 41, 82-86.	1.7	39
184	Role of Pramipexole in the Management of ParkinsonÊ¼s Disease. CNS Drugs, 2010, 24, 829-841.	5.9	48
185	Nonmotor symptoms in Parkinsonâ€™s disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.5	10
186	Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: Focus on sleep and cognitive domains. Journal of the Neurological Sciences, 2010, 289, 44-48.	0.6	99
187	The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. Neuroscience Letters, 2010, 473, 248-251.	2.1	17
188	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. Parkinsonism and Related Disorders, 2010, 16, 522-526.	2.2	45
189	Decreased and increased cortical activation coexist in de novo Parkinson's disease. Experimental Neurology, 2010, 224, 299-306.	4.1	30
190	The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects. Current Alzheimer Research, 2009, 6, 224-237.	1.4	58
191	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1641-1649.	3.9	1,171
192	Implantation of the nucleus tegmenti pedunculopontini in a PSPâ€P patient: Safe procedure, modest benefits. Movement Disorders, 2009, 24, 2020-2022.	3.9	22
193	Bilateral thalamic glioma presenting with parkinsonism. Movement Disorders, 2009, 24, 2168-2169.	3.9	11
194	Unilateral periodic limb movements: Is this a pointer for atypical presentation of corticobasal degeneration syndrome?â€”A case report. Movement Disorders, 2009, 24, 2298-2299.	3.9	4
195	â€œParkinson-dementiaâ€•diseases: A comparison by double tracer SPECT studies. Parkinsonism and Related Disorders, 2009, 15, 762-766.	2.2	25
196	P1.091 Parkinson's disease and pathological gambling: results from a fMRI study investigating cue induced brain activity. Parkinsonism and Related Disorders, 2009, 15, S52.	2.2	1
197	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism and Related Disorders, 2009, 15, S111-S115.	2.2	101
198	Mitochondrial DNA single deletion in a patient with postural tremor. Movement Disorders, 2008, 23, 2098-2100.	3.9	4

#	Article	IF	Citations
199	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. Movement Disorders, 2008, 23, 2049-2054.	3.9	35
200	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Neuroscience Letters, 2008, 444, 83-86.	2.1	11
201	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2008, 14, 266-267.	2.2	0
202	The mtDNA A8344G â€œMERRFâ€•mutation is not a common cause of sporadic Parkinson disease in Italian population. Parkinsonism and Related Disorders, 2008, 14, 381-382.	2.2	13
203	CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Research Bulletin, 2008, 76, 80-84.	3.0	49
204	The safety of dopamine agonists in the treatment of Parkinson's disease. Expert Opinion on Drug Safety, 2008, 7, 111-127.	2.4	9
205	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism and Related Disorders, 2007, 13, 528-531.	2.2	77
206	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neuroscience Letters, 2007, 422, 228-231.	2.1	30
207	Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study. Movement Disorders, 2007, 22, 2170-2175.	3.9	32
208	Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurologica Scandinavica, 2007, 116, 37-42.	2.1	82
209	Lack of association between mtDNA haplogroups and Alzheimerâ€™s disease in Tuscany. Neurological Sciences, 2007, 28, 142-147.	1.9	41
210	Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. Parkinsonism and Related Disorders, 2006, 12, 279-283.	2.2	8
211	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 10, 371-378.	2.6	30
212	Brain perfusion effects of cholinesterase inhibitors in Parkinsonâ€™s disease with dementia. Journal of Neural Transmission, 2006, 113, 1787-1790.	2.8	20
213	Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders, 2006, 21, 1375-1379.	3.9	66
214	Biologic Features (Inflammation and Neoangiogenesis) and Atherosclerotic Risk Factors in Carotid Plaques and Calcified Aortic Valve Stenosis. American Journal of Clinical Pathology, 2006, 126, 494-502.	0.7	39
215	Assessing neuroprotection in Parkinsonâ€™s disease: from the animal models to molecular neuroimaging in vivo. , 2006, , 133-141.		7
216	Biological Features (Inflammation and Neoangiogenesis) and Atherosclerotic Risk Factors in Carotid Plaques and Calcified Aortic Valve Stenosis: Two Different Sites of the Same Disease?. American Journal of Clinical Pathology, 2006, 126, 494-502.	0.7	0

#	Article	IF	Citations
217	From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. Acta Neurologica Scandinavica, 2005, 112, 65-71.	2.1	72
218	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology, 2005, 65, 1971-1973.	1.1	36
219	Psychiatric comorbidity in a population of Parkinson's disease patients. European Journal of Neurology, 2004, 11, 315-320.	3.3	173
220	Presynaptic nigro-striatal function in a group of Alzheimer?s disease patients with parkinsonism: evidence from a dopamine transporter imaging study. Journal of Neural Transmission, 2004, 111, 1065-73.	2.8	45
221	Environmental factors and Parkinson's disease: a caseâ€“control study in the Tuscany region of Italy. Parkinsonism and Related Disorders, 2004, 10, 481-485.	2.2	25
222	Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease. Clinical Neuropharmacology, 2004, 27, 166-170.	0.7	50
223	Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer?s disease. Neurological Sciences, 2003, 24, 162-163.	1.9	36
224	Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. European Journal of Neurology, 2003, 10, 461-462.	3.3	21
225	Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Experimental Neurology, 2003, 182, 421-426.	4.1	70
226	Serotoninergic Polymorphisms (5-HTTLPRand5-HT2A): Association Studies with Psychosis in Alzheimer Disease. Genetic Testing and Molecular Biomarkers, 2003, 7, 309-314.	1.7	47
227	Orthostatic Hypotension in De Novo Parkinson Disease. Archives of Neurology, 2003, 60, 1400.	4.5	93
228	Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model. Acta Neurologica Scandinavica, 2002, 105, 32-39.	2.1	1
229	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse, 2002, 43, 201-207.	1.2	100
230	Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. Atherosclerosis, 2001, 158, 53-59.	0.8	38
231	Familial Progressive supranuclear Palsy. Archives of Neurology, 2001, 58, 1846.	4.5	42
232	SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study. Clinical Neuropharmacology, 2001, 24, 221-227.	0.7	97
233	Limbic encephalitis associated with thymic cancer: a case report. Journal of Neurology, 2001, 248, 1000-1002.	3.6	10
234	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 685-687.	1.9	35

#	Article	IF	Citations
235	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	5.3	246
236	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. Movement Disorders, 2000, 15, 350-352.	3.9	49
237	Paroxetine in Parkinsonâ€™s disease: Effects on motor and depressive symptoms. Neurology, 2000, 55, 1216-1218.	1.1	124
238	Relationship Between Left Ventricular Mass and Endothelium-Dependent Vasodilation in Never-Treated Hypertensive Patients. Circulation, 1999, 99, 1991-1996.	1.6	90
239	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 1999, 45, 577-582.	5.3	306
240	Acute and chronic effects of clozapine in essential tremor. Movement Disorders, 1999, 14, 468-472.	3.9	69
241	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelium-Dependent Vasodilation in Never Treated Hypertensive Patients. Hypertension, 1998, 31, 900-905.	2.7	66
242	Clozapine in Parkinson's disease tremor. Neurology, 1997, 49, 1587-1590.	1.1	94
243	A case of pelvic floor myoclonic jerk syndrome. Movement Disorders, 1996, 11, 331-333.	3.9	4
244	Myopathic involvement in two cases of Hallervorden-Spatz disease. Brain and Development, 1995, 17, 286-290.	1.1	9
245	Clozapine in Huntington's chorea. Neurology, 1994, 44, 821-821.	1.1	58